Your Article Summary
See Latest ArticlesGene expression signatures, clinicopathological features, and individualized therapy in breast cancer
JAMA, 04/03/08
Acharya CR et al. - Incorporation of gene expression signatures into clinical risk stratification can refine prognosis
Methods- Retrospective study of early stage breast carcinoma candidates for adjuvant chemotherapy
- Review of microarray data for 964 clinically annotated breast tumor samples (573 in initial set; 391 in validation cohort)
- Relapse risk scores based on respective clinicopathologic features
- Main outcome measures: gene expression signatures and clinicopathological variables in early stage breast cancer to determine a refined estimation of relapse-free survival and sensitivity to chemotherapy
- In initial 573 pts, prognostically significant clusters as patterns of oncogenic pathway activation and tumor biology/microenvironment states were identified within the low-, intermediate-, and high-risk model cohorts
- Multivariate analyses confirmed independent prognostic value of genomic clusters
- Related, not identical, clusters in the independent validation cohort established reproducibility and validity of pathway deregulation patterns in predicting relapse risk
- The prognostic clinicogenomic clusters showed unique sensitivity patterns to commonly used cytotoxic therapies
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Relevance Score: 74%
Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09
Relevance Score: 72%
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09
Relevance Score: 72%
Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09
Relevance Score: 72%
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09
Relevance Score: 72%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Multi-step binding of ADAMTS-13 to von Willebrand factor
Journal of Thrombosis and Haemostasis, 12/02/09
Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
Breast Cancer Research and Treatment, 12/02/09
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer
Breast Cancer Research and Treatment, 12/02/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
Breast Cancer Research and Treatment, 12/02/09
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer
Breast Cancer Research and Treatment, 12/02/09
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09